Le Lézard
Classified in: Health
Subjects: PDT, MAT

Maricann Launches Kiwi - Simplifying Cannabis for Recreational Consumers


Maricann debuts its first recreational brand, anchored in the idea of simplicity

TORONTO, Sept. 17, 2018 /CNW/ - Maricann Group Inc. (CSE:MARI) (FRANKFURT: 75M) (OTCQB:MRRCF) (the "Company") through its wholly-owned subsidiary Maricann Inc. proudly announces the launch of Kiwi - a straightforward, modern approach to cannabis and the first from the Company's House of Brands - available to Canadian consumers of legal age on October 17, 2018.

Maricann is launching Kiwi as a brand designed to help Canadians learn and experience the product in a straightforward, simple and "jargon-free" way. Rather than launching with technical strains that might confuse new consumers, Kiwi will debut four variants that are easy to follow, regardless of background or expertise. Available in dried flower formats, Kiwi's simple naming system consists of White Feather (High CBD), Hawke's Bay (Balanced), Nelson's Blue (Mid THC) and Flightless Bird (Mid-High THC), which are playful takes on Kiwi's New Zealand-inspired name. Each strain will deliver reliable, consistent sensations that are easy to enjoy.  

"We're in the middle of a rapidly growing industry; one that has sparked a lot of curiosity among consumers. We've built Kiwi to streamline the information and clutter of products - so that cannabis is accessible to a wider public and Canadians can make smart, informed decisions on where we fit in their wellness routine and lifestyle," said Geoff Kosar, Vice President of Sales & Marketing. "At its core, Kiwi is a celebration of the simple pleasures, and that starts with simple, straightforward communications."

Working as Kiwi's Master Grower, industry veteran Jennifer Ayotte brings her exacting standards and dedication to delivering quality cannabis to Maricann's state-of-the-art facilities in Langton, Ontario. "Cannabis can be simple, elegant and easy-to-understand," said Jennifer Ayotte, Kiwi Master Grower. "When the right measures are set in place for consistency, quality and safety, it's easier to see that what we're really talking about are plants."

Visit kiwicannabis.ca for more information on how to simplify your self-care.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of cannabis for medical purposes. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) and will continue to pursue new opportunities in Europe.

Forward Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Maricann, please visit our website at www.maricann.com

SOURCE Maricann Group Inc.


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: